Neoadjuvant Radiotherapy for Breast Cancer

Breast Cancer Clinical Trial

Official title:

Neoadjuvant Radiotherapy Versus Adjuvant Radiotherapy for Breast Cancer: A Phase II Exploratory Randomized Controlled Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06313073
• Other study ID #: CHFL-BC-01
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2024
• Est. completion date: February 15, 2026

Study information

• Verified date: March 2024
• Source: Changhai Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the effects of neoadjuvant radiotherapy and adjuvant radiotherapy in patients with breast cancer. The main questions it aims to answer are: - The clinical effect of neoadjuvant radiotherapy for breast cancer was determined according to the postoperative specimens. - Evaluate the acute and late toxicity of preoperative radiotherapy Participants will be randomly divided into two groups: the neoadjuvant radiotherapy group and the adjuvant radiotherapy group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 15, 2026
• Est. primary completion date: February 15, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Female;
• Age range from 18 to 70 years old;
• The pathological diagnosis is invasive cancer, and immunohistochemical examination has been performed to confirm the status of ER, PR, HER2, Ki67, etc;
• Clarify the BRCA gene mutation status;
• Patients who have a baseline stage of T1-3N0-3M0 and meet one of the following conditions and require neoadjuvant therapy: ? mass>5cm; ? Axillary lymph node metastasis; ? HER-2 positive; ? Three Yin type; ? Those who have a desire to preserve breast, but have a large ratio of tumor size to breast volume, making it difficult to preserve breast;
• Baseline estimation requires adjuvant radiotherapy, which meets one of the following conditions: ? performing breast conserving surgery; ? T3 or N positive patients after mastectomy and axillary dissection; ? After mastectomy, sentinel lymph nodes were positive and axillary dissection was not performed;
• KPS score = 80;
• The tumor must be visible in CT scan;
• Patients must undergo magnetic resonance imaging to help determine the contour of the tumor and exclude other lesions. If other lesions are found, biopsy must be performed on these lesions and the result is negative before continuing treatment;
• No history of serious internal medicine diseases or other serious comorbidities, such as a history of mental illness, allergies, etc;
• Sign an informed consent form.

Exclusion Criteria:

• Clinical or pathological stage T4 or M1 breast cancer;
• Received preoperative neoadjuvant therapy;
• Pathological confirmation shows that there is no invasive cancer component in DCIS;
• Double breast cancer or previous contralateral breast cancer;
• Imaging examination suggests suspicious malignant lesions in the ipsilateral or contralateral breast, which have not been pathologically confirmed to be benign;
• KPS score = 70;
• There is active infection currently;
• Concomitant with severe heart, liver, kidney, hematopoietic and neurological diseases, psychiatric patients, or estimated survival time<6 months;
• History of malignant tumors in other areas, excluding curable non melanoma skin cancer and cervical cancer in situ;
• History of radiation therapy at the site of previous radiation therapy;
• Pregnancy and lactation period;
• Those with poor compliance or life-threatening conditions who cannot complete treatment.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Radiation:
• Neoadjuvant radiotherapy
The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV: 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV: 8.7-10Gy/3-4 Fx.
• adjuvant radiotherapy
The patient received radiotherapy after surgery. CTV : 40Gy/15fx/3w, sequential GTV: 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV: 8.7-10Gy/3-4 Fx.

Locations

Country	Name	City	State
China	Changhai hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Changhai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pCR	pathological complete remission	up to 3 weeks
Secondary	RCB	residual cancer burden	up to 3 weeks